Evaxion Biotech A/S
We are an AI-immunology platform company decoding the human immune system to discover and develop novel immunotherapies for cancer and infectious diseases. We have developed our AI-immunology core technology to deeply understand the biological processes relevant for engaging the immune system so we can harness its powers through novel immunotherapies. Our scalable AI-immunology core technology enables broad applicability across diseases with immunological components. With deep insights into the biological processes of the immune system, we bridge technology, engineering expertise and drug development know-how to bring novel immunotherapies to patients.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Internationally (various countries)
About Us
Through AI platform technologies, we redefine the drug discovery process. Using our deep understanding of the human immune system and our proprietary AI technology, we are able to mimic the human immune system in silico and predict whether the body will have an immune response to certain stimuli.
Based on our state-of-the-art AI platforms PIONEERTM, EDENTM, and RAVENTM, we are advancing a robust product pipeline in immuno-oncology and infectious diseases with primary focus on discovery and early development, building on a simple and scalable business model. We are continuously exploring new frontiers in AI-immunology, including evaluating new therapeutic areas where our know-how and technologies can make a difference such as autoimmune diseases, allergies, microbiome dysbiosis and parasites.